National Bank of Canada
SLS icon

National Bank of Canada’s SELLAS Life Sciences SLS Stock Holding History

National Bank of Canada’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10K Buy
+2,387
New +$10.7K ﹤0.01% 2335

Other funds holding SLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $208B AUM 16.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

National Bank of Canada's SLS Position: Q1 2026 in Review

National Bank of Canada opened a new position in SELLAS Life Sciences (SLS) in Q1 2026: 2,387 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #2335 among its holdings.

160 funds tracked by Wall St. Rank hold SLS as of Q1 2026.

  • National Bank of Canada held 2,387 shares of SELLAS Life Sciences worth $10K as of Q1 2026.
  • SELLAS Life Sciences was a new National Bank of Canada position in Q1 2026.
  • SELLAS Life Sciences made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2335 holding.
  • 160 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.